Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Savara Inc (SVRA)

Savara Inc (SVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,287,952
  • Shares Outstanding, K 203,468
  • Annual Sales, $ 0 K
  • Annual Income, $ -95,880 K
  • EBIT $ -121 M
  • EBITDA $ -126 M
  • 60-Month Beta 0.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.72

Options Overview Details

View History
  • Implied Volatility 447.58% (+60.91%)
  • Historical Volatility 73.41%
  • IV Percentile 91%
  • IV Rank 57.20%
  • IV High 737.00% on 11/11/25
  • IV Low 60.79% on 05/29/25
  • Expected Move (DTE 17) 1.41 (22.29%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 481
  • Volume Avg (30-Day) 306
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 3,637
  • Open Int (30-Day) 6,085
  • Expected Range 4.92 to 7.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.12
  • Number of Estimates 4
  • High Estimate -0.12
  • Low Estimate -0.13
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.55 +14.16%
on 12/02/25
7.01 -9.64%
on 12/12/25
+0.04 (+0.64%)
since 11/28/25
3-Month
3.34 +89.52%
on 10/08/25
7.01 -9.64%
on 12/12/25
+2.81 (+79.83%)
since 09/29/25
52-Week
1.89 +234.92%
on 05/27/25
7.01 -9.64%
on 12/12/25
+3.18 (+100.95%)
since 12/27/24

Most Recent Stories

More News
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

-- The BLA was Resubmitted with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufacturer and Priority Review was Requested --

SVRA : 6.33 (-1.86%)
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team...

SVRA : 6.33 (-1.86%)
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

-- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 -- -- Savara Was Also Recently Granted a European Patent Covering...

SVRA : 6.33 (-1.86%)
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has issued patent No. 4 496...

SVRA : 6.33 (-1.86%)
Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will...

SVRA : 6.33 (-1.86%)
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

-- On Track to Resubmit the Biologics License Application (BLA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) in December and Will Request Priority Review -- ...

SVRA : 6.33 (-1.86%)
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders

NEW YORK , Nov. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit.

SVRA : 6.33 (-1.86%)
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Savara To Contact Him Directly To Discuss Their Options

SVRA : 6.33 (-1.86%)
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA

LOS ANGELES , Nov. 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Savara Inc. ("Savara " or "the Company") (NASDAQ: SVRA ) for violations of...

SVRA : 6.33 (-1.86%)
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Nov. 7, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. ("Savara"...

SVRA : 6.33 (-1.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States.

See More

Key Turning Points

3rd Resistance Point 6.69
2nd Resistance Point 6.59
1st Resistance Point 6.46
Last Price 6.33
1st Support Level 6.24
2nd Support Level 6.14
3rd Support Level 6.01

See More

52-Week High 7.01
Last Price 6.33
Fibonacci 61.8% 5.05
Fibonacci 50% 4.45
Fibonacci 38.2% 3.84
52-Week Low 1.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar